Membranous nephropathy and nonsteroidal anti-inflammatory agents.

Membranous nephropathy presents clinically as nephrotic syndrome, with subepithelial immune complex deposits seen on biopsy. Historically, in about three-quarters of membranous cases, no obvious etiologic agent or condition can be identified. More recently, serum antibodies to the phospholipase A2 receptor have been discovered in many patients with primary/idiopathic membranous nephropathy. About one-quarter of patients have membranous nephropathy as a manifestation of another systemic disorder, such as autoimmune conditions, infection, malignancy, toxin exposure, or drugs (classically gold or penicillamine). In this report, we present a case of recurrent nephrotic syndrome with biopsy-proven membranous nephropathy closely associated with use of the nonsteroidal anti-inflammatory drugs (NSAIDs) naproxen and piroxicam. Characterization of the immunoglobulin G (IgG) subclass profile of the deposits showed abundant IgG1, weak IgG4, and positive staining for phospholipase A2 receptor. This case serves to highlight membranous nephropathy as an under-recognized renal complication of NSAID use. Other kidney effects of NSAIDs, such as hemodynamic compromise, interstitial nephritis, and minimal change disease, are more broadly recognized.

[1]  Ming-hui Zhao,et al.  Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  D. Kleinknecht.  Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. , 1995, Seminars in nephrology.

[3]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[4]  H. Saisho,et al.  Membranous nephropathy associated with oxaprozin treatment. , 1996, Nephron.

[5]  W. J. Klein,et al.  Piroxicam-induced renal disease. , 1984, Archives of Internal Medicine.

[6]  A. Komatsuda,et al.  Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  M. Schwartz,et al.  Heptinstall's Pathology of the Kidney , 2014 .

[8]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[9]  V. D’Agati,et al.  Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. , 2003, Clinical nephrology.

[10]  M. Knotek,et al.  Safe Administration of Celecoxib to a Patient with Repeated Episodes of Nephrotic Syndrome Induced by NSAIDs , 2011, Clinical drug investigation.

[11]  D. Salant,et al.  Anti-phospholipase A2 receptor antibody in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[12]  H. Demiroğlu.  Postrenal transplant erythrocytosis: the roles of testosterone and erythropoietin. , 1997, Clinical nephrology.

[13]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .

[14]  B. Iványi.  A primer on recurrent and de novo glomerulonephritis in renal allografts , 2008, Nature Clinical Practice Nephrology.

[15]  R. Glassock.  Secondary membranous glomerulonephritis. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  A. Magnano,et al.  Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[17]  E. Messias,et al.  Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies , 2013, Modern Pathology.

[18]  N. Takahashi,et al.  Membranous glomerulonephritis is a manifestation of IgG4-related disease. , 2013, Kidney international.

[19]  T. Larson,et al.  Reversible Membranous Nephropathy Associated With the Use of Nonsteroidal Anti-inflammatory Drugs , 1996 .

[20]  T. Uzu,et al.  Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. , 2007, Internal medicine.